Nebuhaler - Assists in the effective use of AstraZeneca’s pMDIs by patients who have problems co-ordinating actuation of the inhaler with inhalation

Most infants and young children have not developed the co-ordination to enable effective use of pMDIs. Nebuhaler is a spacer device which is easy to use and enables effective drug delivery to these patients.

1.	Pool JB, et al. Arch Dis Child 1988; 63: 288–91

1. Pool JB, et al. Arch Dis Child 1988; 63: 288–91

In 18 of 22 asthmatic children aged between 2–5 years, inhalation of terbutaline 500 µg through Nebuhaler resulted in clinically significant improvement in functional residual capacity. Improvement in functional residual capacity and peak flow rate was noted in all ten asthmatic children in a 5–7 year-old group.

Terbutaline delivered via Nebuhaler results in improvement in functional residual capacity in patients aged 2-5 years

Adapted from Pool et al., 1988.

back to top